Gene
ERBB3
ERBB3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (68), Actionable biomarkers (8), Trial mentions (116), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ERBB3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 23 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 16 of 8,738 | 0.18% | not measured | |
| 2025 | 21 of 8,875 | 0.24% | not measured | |
| 2024 | 18 of 8,597 | 0.21% | not measured | |
| 2023 | 9 of 8,275 | 0.11% | 37 of 11,460 | 0.32% |
| 2022 | 7 of 8,285 | 0.08% | 38 of 13,598 | 0.28% |
| 2021 | 4 of 8,692 | 0.05% | 30 of 15,045 | 0.20% |
| 2020 | 5 of 7,640 | 0.07% | 28 of 14,459 | 0.19% |
| 2019 | 3 of 7,300 | 0.04% | 41 of 12,159 | 0.34% |
| 2018 | 3 of 6,927 | 0.04% | 27 of 11,854 | 0.23% |
| 2017 | 4 of 6,558 | 0.06% | 50 of 11,595 | 0.43% |
Showing 10 of 37 years.
Assay-provider ledger (68)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Belay Diagnostics | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| Genetron Health | Diagnostic provider | Clinical validation | 1 | September 27, 2024 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 2 | September 27, 2024 |
| ZYMO Research (Orange, CA) | Reagent supplier | Clinical validationAnalytical validation | 2 | September 27, 2024 |
| NanoString | Unclassified | Clinical validation | 1 | December 20, 2023 |
Showing 5 of 68 assay-provider companies.
Actionable biomarkers (8)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ERBB3 amplification | Egfr Mab Inhibitors | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| ERBB3 (P262H,G284R,Q809R) | LAPATINIB | response-associated | No disease recorded | Cancer Genome Interpreter |
| ERBB3 (P262H,G284R,Q809R) | TRASTUZUMAB | response-associated | No disease recorded | Cancer Genome Interpreter |
| ERBB3 (G284R,R103G) | AFATINIB | response-associated | No disease recorded | Cancer Genome Interpreter |
| ERBB3 (P262H,G284R) | Erbb3 Mab Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 8 actionable-biomarker assertions.
Trial mentions (116)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07597369 | Trial biospecimen (AACT) |
| NCT05769764 | Trial biospecimen (AACT) |
| NCT05653752 | Trial eligibility (AACT) |
| NCT06439771 | Trial eligibility (AACT) |
| NCT02134015 | Trial eligibility (AACT) |
Showing 5 of 116 trial mentions.
Target-disease associations (487)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 487 associations.
Vendor sourcing (355)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.0.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Canonic... | View ClinVar record SCV006585601.1 |
| Akeso | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Prior human epidermal growth factor receptor 3 (HER3) -targeted therapies, including antibodies, antibody-drug conjugates (ADCs), chimeric antigen rece... | View trial NCT06730386 |
| Akeso | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Prior human epidermal growth factor receptor 3 (HER3) -targeted therapies, including antibodies, antibody-drug conjugates (ADCs), chimeric antigen rece... | View trial NCT07281326 |
| Akeso | Trial sponsor | Mentioned in trial textTrial free-text mention | HER3 | View trial NCT06730386 |
| Akeso | Trial sponsor | Mentioned in trial textTrial free-text mention | HER3 | View trial NCT07281326 |
Showing 5 of 355 sourcing records.
Trial-cited literature (466)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer. | The New England journal of medicine | 2025 | 103 |
| Recent advances in therapeutic strategies for non-small cell lung cancer. | Journal of hematology & oncology | 2025 | 100 |
| Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. | Nature medicine | 2025 | 24 |
| A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. | Nature medicine | 2025 | 20 |
| Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trial. | Nature medicine | 2025 | 17 |
Showing 5 of 466 papers.
Protein variant mentions (11)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D297Y | 2 | 2016 to 2019 | PMID 30951733, PMID 26619011 |
| p.E928G | 3 | 2018 to 2021 | PMID 33663941, PMID 31806627, PMID 29349598 |
| p.F94L | 1 | 2019 | PMID 30951733 |
| p.G284R | 4 | 2013 to 2023 | PMID 37634629, PMID 34011535, PMID 30951733 |
| p.K747N | 1 | 2015 | PMID 25741868 |
Showing 5 of 11 variants.
Human sample screening reference (7)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.E928G | ALCHEMIST-ALCH | Not Reported; Not Reported | 1 | 1,170 | 0.09% | 0.02% to 0.48% |
| p.E928G | CMI-MBC | Ductal and Lobular Neoplasms; Breast | 2 | 174 | 1.15% | 0.32% to 4.09% |
| p.E928G | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 3 | 1,098 | 0.27% | 0.09% to 0.80% |
| p.E928G | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.E928G | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Showing 5 of 7 cohort observations.
Literature-extracted relations (94)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Vemurafenib | Chemical | negative_correlate |
Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. | 2022 |
| Sorafenib | Chemical | positive_correlate |
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 |
| VORINOSTAT | Chemical | positive_correlate |
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer. | 2020 |
| TRASTUZUMAB | Chemical | positive_correlate |
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. | 2018 |
| TELMISARTAN | Chemical | negative_correlate |
Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. | 2017 |
Showing 5 of 94 relation assertions.
Organizations publishing (411)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 39 | 2011 to 2025 |
| Dana-Farber Cancer Institute | Other | 26 | 2008 to 2025 |
| The University of Texas System | Academic | 21 | 2013 to 2025 |
| Harvard Medical School | Academic | 17 | 2009 to 2023 |
| Vanderbilt Health | Industry | 17 | 2001 to 2024 |
Showing 5 of 411 organizations.
Where ERBB3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
404 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.